Abstract:Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of obtaining further knowledge on this disorder. Methods: Patients who met DRD genetic diagnostic criteria through whole-exome sequencing and took levodopa for over 3 years were included in our study. Detailed information was collected on these patients, including family history, age at onset, age and dosage at starting levodopa, current medication and dosage, levodopa duration, diurnal fluctuation, and other clinical features. The Burke–Fahn–Marsden Dystonia Rating Scale-Motor (BFMDRS-M) score was used to evaluate patients' dystonia and variation after levodopa. According to the long-term outcomes, patients were further graded as good (dystonia improved by more than 50% after levodopa, and no further motor symptoms appeared) and poor (dystonia improved by <50% after levodopa, or new motor symptoms appeared). Results: A total of 20 DRD patients were included (11 with GCH1 variants, 9 with TH variants). During long-term levodopa treatment, three patients with TH variants (3/20, 15%) developed motor symptoms, including body jerks and paroxysmal symptoms, and responded well to increasing levodopa doses. The patient with homozygous mutation c.1481C>T/p. Thr494Met harbored more serious symptoms and poor response to levodopa and showed decreased cardiac uptake in MIBG. Conclusions: Most DRD patients showed satisfactory treatment outcomes after long-term levodopa, whereas few patients with TH variants presented motor symptoms, which is considered to be related to dopamine insufficiency. For patients with motor symptoms after long-term levodopa, increasing the dose slowly might be helpful to relieve symptoms.

Four novel mutations in the GCH1 gene of Chinese patients with dopa-responsive dystonia.

Analysis of Clinical Phenotype and CGH1 Gene Mutations in a Family Affected with Dopa-Responsive Dystonia

Novel GCH1 mutation and clinical study Chinese patients with dopa-responsive dystonia

A Novel Tyrosine Hydroxylase Variant in a Group of Chinese Patients with Dopa-Responsive Dystonia.

[Mutation Analysis of GCH1 Gene in Chinese Patients with Dopa Responsive Dystonia].

Two Novel Mutations of the GTP Cyclohydrolase 1 Gene and Genotype–phenotype Correlation in Chinese Dopa-responsive Dystonia Patients

A Novel Missense Mutation in Gtp Cyclohydrolase I (gch1) Gene Causes Dopa-Responsive Dystonia in Chinese Han Population

GTP Cyclohydrolase I and Tyrosine Hydroxylase Gene Mutations in Familial and Sporadic Dopa-Responsive Dystonia Patients.

Molecular Genetics of Dopa-Responsive Dystonia in Chinese

Han Chinese Patients with Dopa-Responsive Dystonia Exhibit a Low Frequency of Exonic Deletion in the GCH1 Gene

Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia families.

Molecular genetic study of Han nationality dopa-responsive dystonia in three Chinese families

Hereditary Dopa-Responsive Dystonia: Report of a Family

[Clinical Analysis of Dopa-Responsive Dystonia and Mutation Analysis of the GCH I Gene].

Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.

Study of GCH1 and TH genes in Chinese patients with Parkinson's disease.

Three Novel Mutations of the Spastin Gene in Chinese Patients with Hereditary Spastic Paraplegia

PRRT2 mutations in a cohort of Chinese families with paroxysmal kinesigenic dyskinesia and genotype-phenotype correlation reanalysis in literatures.

Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes

Clinical and genetic characteristics of dopamine-responsive dystonia in 3 children

DYT1 MUTATIONS AMONGST EARLY ONSET PRIMARY DYSTONIA PATIENTS IN CHINA